I like your comparisome between the CHM frug and the IMU drug.
The IMU share price was 3.6c march 20. It closed down today at 42c.
The patient cohort for the Her vaxx have a normal life expectency of 12 months when entering the trial. Her vaxx extended that to 18 months and the share price popped.
GBM patients have a life expectency of 6 months when entering the trial. They have no real effect SOC option. So CHM will be able to show statisical significant results at a much early time through the trial than what IMU could. The unmet need of GBM treatment will drive the accerated approval pathway if results are good. CarT also works faster than B cell immunology process. But historically, the T cells have far more adverse events than B cell tech. CHM belive they have fixed this.
So I agree with you. Good results showing safety and effecacy in Nov could well be pivotal share price wise. It could also be the first time CarT has been shown to work on solid tumors. 100 million market cap is very very cheap if we get good results.
Remember as well, GBM is only one of many indications this drug may be trialed on.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)